William Blair Reaffirms Outperform Rating for Viking Therapeutics (VKTX)

Share on StockTwits

William Blair reissued their outperform rating on shares of Viking Therapeutics (NASDAQ:VKTX) in a research report report published on Thursday.

VKTX has been the subject of a number of other research reports. Raymond James upgraded Viking Therapeutics from an outperform rating to a strong-buy rating and set a $43.00 price objective for the company in a research report on Monday, November 19th. They noted that the move was a valuation call. B. Riley assumed coverage on Viking Therapeutics in a research report on Tuesday, December 11th. They issued a buy rating and a $16.00 price objective for the company. BidaskClub upgraded Viking Therapeutics from a strong sell rating to a sell rating in a research report on Wednesday, January 2nd. Svb Leerink assumed coverage on Viking Therapeutics in a research report on Friday, February 22nd. They issued a mkt perform rating for the company. Finally, Leerink Swann assumed coverage on Viking Therapeutics in a research report on Friday, February 22nd. They issued a market perform rating and a $10.00 price objective for the company. One analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the company’s stock. The company currently has a consensus rating of Buy and an average price target of $22.88.

NASDAQ:VKTX traded up $0.06 during mid-day trading on Thursday, hitting $7.78. 1,233,025 shares of the company’s stock traded hands, compared to its average volume of 2,875,690. Viking Therapeutics has a 12 month low of $3.69 and a 12 month high of $24.00. The company has a market cap of $570.25 million, a price-to-earnings ratio of -9.85 and a beta of 2.73.

Viking Therapeutics (NASDAQ:VKTX) last announced its earnings results on Wednesday, March 13th. The biotechnology company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.03. On average, research analysts predict that Viking Therapeutics will post -0.43 EPS for the current fiscal year.

Several hedge funds have recently made changes to their positions in the business. FMR LLC acquired a new position in shares of Viking Therapeutics in the 3rd quarter worth approximately $125,858,000. Fiera Capital Corp bought a new position in shares of Viking Therapeutics in the 4th quarter worth $11,167,000. BlackRock Inc. boosted its position in shares of Viking Therapeutics by 22.4% in the 4th quarter. BlackRock Inc. now owns 4,099,406 shares of the biotechnology company’s stock worth $31,361,000 after purchasing an additional 749,505 shares during the last quarter. Jennison Associates LLC bought a new position in shares of Viking Therapeutics in the 3rd quarter worth $9,501,000. Finally, Vanguard Group Inc boosted its position in shares of Viking Therapeutics by 21.4% in the 3rd quarter. Vanguard Group Inc now owns 2,877,287 shares of the biotechnology company’s stock worth $50,123,000 after purchasing an additional 508,097 shares during the last quarter. Institutional investors own 65.69% of the company’s stock.

About Viking Therapeutics

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures.

Further Reading: Mutual Funds

Analyst Recommendations for Viking Therapeutics (NASDAQ:VKTX)

Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Schwartz Investment Counsel Inc. Has $1.91 Million Stake in Citigroup Inc
Schwartz Investment Counsel Inc. Has $1.91 Million Stake in Citigroup Inc
Robeco Institutional Asset Management B.V. Buys 400 Shares of Whirlpool Co.
Robeco Institutional Asset Management B.V. Buys 400 Shares of Whirlpool Co.
Ingredion Inc  Shares Bought by Robeco Institutional Asset Management B.V.
Ingredion Inc Shares Bought by Robeco Institutional Asset Management B.V.
Valley National Bancorp  Shares Bought by Rhumbline Advisers
Valley National Bancorp Shares Bought by Rhumbline Advisers
iRobot Co.  Shares Bought by Rhumbline Advisers
iRobot Co. Shares Bought by Rhumbline Advisers
Vanguard FTSE Europe ETF  Holdings Cut by Global Retirement Partners LLC
Vanguard FTSE Europe ETF Holdings Cut by Global Retirement Partners LLC


© 2006-2019 Ticker Report